AVIR stock icon

Atea Pharmaceuticals
AVIR

$3.43
1.78%
 

About: Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Employees: 74

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

30% more capital invested

Capital invested by funds: $168M [Q4 2023] → $219M (+$51.2M) [Q1 2024]

27% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 15

4% more funds holding

Funds holding: 106 [Q4 2023] → 110 (+4) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

1.48% less ownership

Funds ownership: 66.02% [Q4 2023] → 64.54% (-1.48%) [Q1 2024]

13% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 39

92% less call options, than puts

Call options by funds: $494K | Put options by funds: $6.38M

Research analyst outlook

We haven’t received any recent analyst ratings for AVIR.

Financial journalist opinion